# 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS SASTM FluAlert A & B Test

This $5 1 0 ( \pmb { k } )$ summary of safety and effectiveness submission is in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Submitted by:

SA Scientific, Ltd. 4919 Golden Quail San Antonio, TX 78240 210-699-8800

JUL 8 3 2009

# Establishment Reg. No:

1645225

Contact Person:

Robbi Perry

Date Prepared:

July 20, 2009

Proprietary Name:

SASTM FluAlert A & B Test

Classification Name:

Antigens, CF (including CF control), Influenza virus A, B, C

Device Classification:

21 CFR Part 866.3330

Regulatory Class:

Class II

Classification Advisory Committee:

Microbiology

Product Code:

GNX

Substantial Equivalence:

Substantially equivalent to the $\mathsf { S A S ^ { r m } }$ individual devices-SASTM Influenza A Test (K044141) and SASTM Influenza B Test (K041439), manufactured by SA Scientific, Ltd., San Antonio, TX.

Device Description:

The SASTM FluAlert A & B Test utilizes antibodies against influenza type A and influenza type B viral nucleoproteins. After the extraction has been completed, the sample is placed into two separate sample wells. The specimen is absorbed and migrates via capillary action through membranes that contain dried gold conjugated antibody, which is specific for either influenza A or influenza B viral nucleoproteins. If these nucleoproteins are present, a "half-sandwich" immunocomplex is formed. The membrane contains immobilized antibody to influenza A or influenza B nucleoproteins, respectively, which bind the "half sandwich" complex. Thus, in the presence of influenza nucleoproteins, a "whole sandwich" immunocomplex is formed and a visible, pink-colored line develops in the specimen zone of the test device. In the absence of an influenza antigen, a "sandwich" immunocomplex is not formed and a negative result is indicated. To serve as a procedural control, a pink-colored control line will always appear in the control zone of each strip regardless of the presence or absence of influenza A or influenza B nucleoproteins.

Intended Use:

SASTM FluAlertA&B Test is a visual and rapid assay for the presumptive invitro qualitative detection of influenza A and influenza B viral nucleoprotein antigens from nasal washes and nasal aspirates of symptomatic patients. Negative results should be confirmed via culture. This test is not intended for the detection of Influenza Type C viral antigen. This test is for professional use only.

Negative results do not preclude infection with influenza A or B and should not be used as the sole basis for treatment or other patient management decisions. It is recommended that negative results be confirmed by cell culture.

Conditions for Use:

For prescription use only.

Quality Controls:

The SASTM Influenza A & Influenza B Test provides two (2) internal procedural quality controls. It is recommended that external quality controls be assayed following the user's laboratory's standard quality control procedures and in conformance with local, state and federal regulations or accreditation organizations as applicable

Device comparison:

The $\mathbf { S } \mathbf { A } \mathbf { S } ^ { \mathbf { T M } }$ Influenza A & Influenza B tests are rapid immunoassay tests utilizing immunochromatographic technology for the visualization of Influenza A & Influenza B viral nucleoprotein antigens. Each utilizes an antibody conjugated to colored particles and an antibody printed onto a membrane. The chemistry of the predicate devices and the proposed device is identical; the only differnice is the plastic cassette.

Performance Summary:

The SASTM FluAlert A&B test performed substantially equivalent to the predicate devices, SASTM Influenza A and SAS Influenza Flu B Tests mentioned above. This was verified by comparison to freshly collected nasal wash and nasal aspirate specimens.

Cross-reactivity and interference studies were performed on viral and bacterial strains commonly found in the human respiratory tract. None of the organisms interfered or cross-reacted with the performance of the SASTM FluAlert A& B test.

Clinical Summary:

Prospective Clinical Study:

The SASTM FluAlert A&B Test combines the immunoassay test strips from the individual ${ \tt S A S T M }$ Influenza A and SASTM Influenza B Tests into one side-byside plastic cassette. There are no other changes made to this test. In these studies, the users compared the combined test to the individual tests for evaluation of user interpretations. Please see: "Results Summary: SASTM Influenza A and $\mathtt { S A S ^ { m } }$ Influenza B Individual Devices compared to cell culture or DFA" chart for comparison of the individual tests to cell culture/DFA.

Four clinical trial sites, in Texas and South Dakota, tested four hundred sixty one (461) nasal clinical specimens blindly and prospectively comparing the $\pmb { \ S A } \pmb { \ S } ^ { \mathsf { T M } }$ Influenza A Test and The SASTM FluAlert A&B (combined) Test performance. The $\mathtt { S A S ^ { T M } }$ Influenza A Test and ${ \bar { \mathbf { S } } } { \mathbf { A } } { \bar { \mathbf { S } } } ^ { \mathbf { T M } }$ FluAlert A&B Test had a positive percent agreement of $9 7 . 2 \%$ and a negative percent agreement of $9 9 . 7 \%$ Thirteen samples yielded invalid results. These data were not included in the totals.

Four clinical trial sites, in Texas and South Dakota, tested four hundred sixty one (461) nasal clinical specimens blindly and prospectively comparing the $\mathsf { S A S ^ { T M } }$ Influenza B Test and the SASTM FluAlert A&B (combined) Test performance. The $\mathtt { S A S T M }$ Influenza B test and SASTM FluAlert A&B Test had a positive percent agreement of $9 8 . 7 \%$ and a negative percent agreement of $9 9 . 7 \%$ .

Clinical sites collected the nasal wash samples from an approximately equal mix of adult $( > 2 1$ years) and pediatric patients (0-21 years). The nasal aspirate samples were collected predominately from pediatric patients.

Fresh Prospective Nasal Aspirates:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>SAS Influenza A</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>SASA/BCombo</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>44</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>138</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>182</td></tr><tr><td rowspan=1 colspan=5>Positive % Agreement: 97.8%(95% CI 87-100%)</td></tr><tr><td rowspan=1 colspan=5>Negative % Agreement: 100% (97% CI 95-100%)</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>SAS Influenza B</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>SASA/BCombo</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>37</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>145</td><td rowspan=1 colspan=1>145</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>145</td><td rowspan=1 colspan=1>182</td></tr><tr><td rowspan=1 colspan=5>Positive % Agreement: 100%(95%CI 97-100%)</td></tr><tr><td rowspan=1 colspan=5>Negative % Agreement: 100% (95% CI88-100%)</td></tr></table>

# Fresh Prospective Nasal Washes:

<table><tr><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">SAS Influenza A</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="3">SASA/BCombo</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">27</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">251</td><td colspan="1" rowspan="1">252</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">252</td><td colspan="1" rowspan="1">279</td></tr><tr><td colspan="5" rowspan="1">Positive % Agreement: 96.3% (95% CI 79-100%)</td></tr><tr><td colspan="5" rowspan="1">Negative % Agreement: 99.6% (95%CI 97-100%)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">SAS Influenza B</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="3">SASA/BCombo</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">41</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">237</td><td colspan="1" rowspan="1">238</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">238</td><td colspan="1" rowspan="1">279</td></tr><tr><td colspan="5" rowspan="1">Positive % Agreement: 97.6% (95% CI 86-100%)</td></tr><tr><td colspan="5" rowspan="1">Negative % Agreement: 99.6% (95% CI 97-100%)</td></tr></table>

# Results Summary: Fresh Nasal Washes and Aspirates:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>SAS Influenza A</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>SASA/BCombo</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>71</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>388</td><td rowspan=1 colspan=1>390</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>389</td><td rowspan=1 colspan=1>461</td></tr><tr><td rowspan=1 colspan=5>Positive % Agreement: 97.2% (95% CI 89-100%)</td></tr><tr><td rowspan=1 colspan=5>Negative % Agreement: 99.7% (95% CI 98-100%)</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>SAS Influenza B</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>SASA/BCombo:</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>78</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>382</td><td rowspan=1 colspan=1>383</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>383</td><td rowspan=1 colspan=1>461</td></tr><tr><td rowspan=1 colspan=5>Positive % Agreement: 98.7% (95% CI 92-100%)</td></tr><tr><td rowspan=1 colspan=5>Negative % Agreement: 99.7% (95% CI 98-100%)</td></tr></table>

# Note: Performance characteristics for detecting the 2009 H1N1 influenza virus from human specimens have not been established

Demographics of Fresh Samples:   

<table><tr><td rowspan=1 colspan=1>Age (years)</td><td rowspan=1 colspan=1>Number of NasalWash specimens</td><td rowspan=1 colspan=1>% of TotalNWSpecimens</td><td rowspan=1 colspan=1>Number of NasalAspirateSpecimens</td><td rowspan=1 colspan=1>% of TotalNA Specimens</td></tr><tr><td rowspan=1 colspan=1>0-5</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>40.1%</td></tr><tr><td rowspan=1 colspan=1>6-21</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>59.3%</td></tr><tr><td rowspan=1 colspan=1>22 - 65</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>9.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.6%</td></tr><tr><td rowspan=1 colspan=1>&gt;65</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Not Determined</td><td rowspan=1 colspan=1>208</td><td rowspan=1 colspan=1>74.5%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1>cYanmaGeYellowb</td><td rowspan=1 colspan=1>182</td><td rowspan=1 colspan=1></td></tr></table>

Retrospective Study:

To supplement the prospective study, 191 frozen, archived, nasal wash samples from a children's hospital in Texas were blindly assayed comparing the individual ${ \bar { \mathbf { S } } } { \mathbf { A } } { \bar { \mathbf { S } } } ^ { \mathbf { T M } }$ Influenza A Test and the individual $\mathbf { S } \mathbf { A } \mathbf { S } ^ { \mathbf { T M } }$ Inflluenza B Test to the ${ \tt S A S ^ { T M } }$ FluAlert A&B (combined) Test. For these samples, the positive percent agreement with the Influenza A Test is $100 \%$ and negative percent agreement is $9 9 . 3 \%$ , while positive percent agreement with the Influenza B Test was $9 4 . 7 \%$ and negative percent agreement is $9 8 . 0 \%$

<table><tr><td colspan="4">SASTM Influenza A Test</td></tr><tr><td rowspan="4">+</td><td>+ 27</td><td>• 1</td><td>28</td></tr><tr><td>0</td><td>163</td><td>163</td></tr><tr><td>27</td><td>164</td><td>191</td></tr><tr><td colspan="3"></td></tr></table>

SASTM Flu Alert A&B Combined Test Total

Positive $\%$ Agreement: $100 \%$ $( 9 \overline { { 5 \% } } \mathrm { ~ C I ~ } 8 4 \mathrm { - 1 0 0 \% } )$ EPY Negative $\%$ Agreement: $9 9 . 3 \%$ $9 5 \%$ CI 96-100%)

SASTM FluAlert A & B Combined Test Total

SASTM Influenza B Test   

<table><tr><td rowspan="6">+ *</td><td>36</td><td>3</td><td>39</td></tr><tr><td>2</td><td>150</td><td>152</td></tr><tr><td></td><td></td><td></td></tr><tr><td>38</td><td>153</td><td>191</td></tr></table>

Positive $\%$ Agreement: $9 4 . 7 \%$ $( 9 5 \% \mathrm { C I } 8 1 . 9 9 \% )$ Negative $\%$ Agreement: $9 8 . 0 \%$ $( 9 5 \% \mathrm { C I } 9 4 { - } 9 9 \% )$

Reproducibility:

The reproducibility of the SASTM FluAlert A&B Test was evaluated at three clinical sites. Three or four non-professional users per site tested the SASTM FluAlert A&B Test against a panel of approximately 30 aliquots each of six (6) panel members over a two-week period. Specimens were comprised of pooled nasal aspirates and included two (2) levels of positives for influenza A and two (2) for influenza B and two (2) negatives. The low and medium positives for influenza A contained H3N2 A/Hong Kong/8/68 and the low and medium positives for influenza B contained B/Allen/45. Negative specimens for influenza A contained H3N2 A/Hong Kong/8/68 and negative specimens for influenza B contained B/Allen/45, but both were in concentrations below the limit of detection. Although 30 aliquots of each were prepared, in some cases the total number was fewer than 30 because of spillage or pipetting errors.

Analytical Sensitivity (Limit of Detection):   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Panel Member</td><td rowspan=1 colspan=1>InfluenzaAHighNegative</td><td rowspan=1 colspan=1>Influenza ALow Positive</td><td rowspan=1 colspan=1>Influenza AModeratePositive</td><td rowspan=1 colspan=1>InfluenzaBHighNegative</td><td rowspan=1 colspan=1>InfluenzaBLow Positive</td><td rowspan=1 colspan=1>Influenza BModeratePositive</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Viral TiterFinalConcentrationTCID^{%/0.2 ml.</td><td rowspan=1 colspan=1>1.8 x 103</td><td rowspan=1 colspan=1>7x 10</td><td rowspan=1 colspan=1>1.4x 104</td><td rowspan=1 colspan=1>2.8 x 102</td><td rowspan=1 colspan=1>1.1 x 103</td><td rowspan=1 colspan=1>2.2 x 10 {</td></tr><tr><td rowspan=2 colspan=1>AgreementwithExpectedResult</td><td rowspan=1 colspan=1>Site I</td><td rowspan=1 colspan=1>29 Neg/3096.7%</td><td rowspan=1 colspan=1>26 Pos/3086.6%</td><td rowspan=1 colspan=1>29 Pos/3096.7%</td><td rowspan=1 colspan=1>28 Neg/2996.6%</td><td rowspan=1 colspan=1>29 Pos/3096.7%</td><td rowspan=1 colspan=1>29 Pos/29100%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>29 Neg/3096.7%</td><td rowspan=1 colspan=1>26 Pos/2989.7%</td><td rowspan=1 colspan=1>29 Pos/29100%</td><td rowspan=1 colspan=1>30 Neg/30100%</td><td rowspan=1 colspan=1>29 Pos/3096.7%</td><td rowspan=1 colspan=1>30 Pos/30100%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>. 28 Neg/3093.3%</td><td rowspan=1 colspan=1>27 Pos/3090.0%</td><td rowspan=1 colspan=1>30 Pos/30100%</td><td rowspan=1 colspan=1>26 Neg/2989.7%</td><td rowspan=1 colspan=1>29 Pos/3096.7%</td><td rowspan=1 colspan=1>30 Pos/30100%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>TotalAgreement</td><td rowspan=1 colspan=1>95.6%</td><td rowspan=1 colspan=1>88.8%</td><td rowspan=1 colspan=1>98.9%</td><td rowspan=1 colspan=1>95.4%</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>100%</td></tr></table>

The limit of detection (LOD) for the $\mathtt { S A S ^ { T M } }$ FluAlert A&B Test was determined for five (5) each influenza A and Influenza B viral strains. Each strain was received from ATCC with a known $\mathrm { T C I D } _ { 5 0 }$ concentration. Each strain was serially diluted in SASTM FluAlert extraction buffer. Strains were assayed in triplicate using the SASTM FluAlert A&B Test until no positive signal could be seen. Results are summarized below.

<table><tr><td rowspan=1 colspan=1>InfluenzaViral Strain</td><td rowspan=1 colspan=1>ATCC</td><td rowspan=1 colspan=1>LoDTCID50/0.2 ml</td></tr><tr><td rowspan=1 colspan=1>H1N1 A/PR/3/34</td><td rowspan=1 colspan=1>VR-95</td><td rowspan=1 colspan=1>1.2x 10^}$</td></tr><tr><td rowspan=1 colspan=1>H3N2 A/Aichi/2/68</td><td rowspan=1 colspan=1>VR-547</td><td rowspan=1 colspan=1>5.6 x 10^{2</td></tr><tr><td rowspan=1 colspan=1>H3N2 A/HongKong/8/6/8</td><td rowspan=1 colspan=1>VR-544</td><td rowspan=1 colspan=1>3.5 x 103</td></tr><tr><td rowspan=1 colspan=1>HIN1 A/FM/147</td><td rowspan=1 colspan=1>VR-97</td><td rowspan=1 colspan=1>7.9 x 10^$</td></tr><tr><td rowspan=1 colspan=1>H3N2A/Victoria/3/75</td><td rowspan=1 colspan=1>VR-822</td><td rowspan=1 colspan=1>4.5 x 10}$</td></tr><tr><td rowspan=1 colspan=1>Influenza BB/Lee/40</td><td rowspan=1 colspan=1>VR-101</td><td rowspan=1 colspan=1>9.9 x 104</td></tr><tr><td rowspan=1 colspan=1>Influenza BB/Allen/45</td><td rowspan=1 colspan=1>VR-102</td><td rowspan=1 colspan=1>5.6 x 102</td></tr><tr><td rowspan=1 colspan=1>Influenza BB/Mass/3/66</td><td rowspan=1 colspan=1>VR-523</td><td rowspan=1 colspan=1>4.5 x 102</td></tr><tr><td rowspan=1 colspan=1>Influenza BB/Taiwan/2/62</td><td rowspan=1 colspan=1>VR-295</td><td rowspan=1 colspan=1>3.5 x 101</td></tr><tr><td rowspan=1 colspan=1>Influenza BB/Maryland/1/59</td><td rowspan=1 colspan=1>VR-296</td><td rowspan=1 colspan=1>1.6 x 10^2</td></tr></table>

Twenty-two virus strains were obtained from ATCC or other commercial sources. Each cultured viral strain was tested on the $\mathrm { S A S ^ { T M } }$ FluAlert A&B Test in these concentrations. The results are summarized below.

<table><tr><td rowspan=1 colspan=1>Virus</td><td rowspan=1 colspan=1>ATTC/Lot #</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>&quot;A&quot; portion of theSASTM FluAlertA&amp;B</td><td rowspan=1 colspan=1>&quot;B&quot; portion of theSASTM FluAlertA&amp;B</td></tr><tr><td rowspan=1 colspan=1>Adenovirus 5</td><td rowspan=1 colspan=1>10-198-000</td><td rowspan=1 colspan=1>1.2x 10^0</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Adenovirus 7</td><td rowspan=1 colspan=1>VR7</td><td rowspan=1 colspan=1>3.2 x 10³ TCID50/0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Adenovirus 10</td><td rowspan=1 colspan=1>VR1087</td><td rowspan=1 colspan=1>3.2 x 10^³ TCID50/0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>CoxsackieA9</td><td rowspan=1 colspan=1>VR186</td><td rowspan=1 colspan=1>3.2 x 10^2 TCID50/0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>CoxsackieB5</td><td rowspan=1 colspan=1>VR185</td><td rowspan=1 colspan=1>3.2 x 10 TCID5p/0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Ncg</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus</td><td rowspan=1 colspan=1>021301</td><td rowspan=1 colspan=1>20 μg/ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Echovirus11</td><td rowspan=1 colspan=1>VR1052</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Echovirus3</td><td rowspan=1 colspan=1>VR1040</td><td rowspan=1 colspan=1>1 x 104 TCID5g /0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Echovirus 6</td><td rowspan=1 colspan=1>VR1044</td><td rowspan=1 colspan=1>3.2 x 10b TCID5o/0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>HSV-1</td><td rowspan=1 colspan=1>2J30000</td><td rowspan=1 colspan=1>15 μg/ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Ncg</td></tr><tr><td rowspan=1 colspan=1>HSV-2</td><td rowspan=1 colspan=1>8J29502</td><td rowspan=1 colspan=1>15 μg/ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Varicella zoster</td><td rowspan=1 colspan=1>1102097</td><td rowspan=1 colspan=1>12 μg/ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 1</td><td rowspan=1 colspan=1>VR907</td><td rowspan=1 colspan=1>5.6 x 106 TCID50/0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 2</td><td rowspan=1 colspan=1>VR92</td><td rowspan=1 colspan=1>1.8 x 10^ TCID50/0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 3</td><td rowspan=1 colspan=1>VR93</td><td rowspan=1 colspan=1>3.2 x 106 TCID50/0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>RSV Long</td><td rowspan=1 colspan=1>VR26</td><td rowspan=1 colspan=1>0.1 x 1035 TCID50/0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>RSVB</td><td rowspan=1 colspan=1>VR1400</td><td rowspan=1 colspan=1>0.1 x 103.25 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Influenza B Allen</td><td rowspan=1 colspan=1>VR102</td><td rowspan=1 colspan=1>3.2 x 10³ TCID50/0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza B Lee</td><td rowspan=1 colspan=1>VR101</td><td rowspan=1 colspan=1>3.2 x 106 TCID50/0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza B Mass</td><td rowspan=1 colspan=1>VR523</td><td rowspan=1 colspan=1>1.8 x 10³3 TCID50/0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza BMaryland</td><td rowspan=1 colspan=1>VR296</td><td rowspan=1 colspan=1>1 x 10 TCID5o /0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza BTaiwan</td><td rowspan=1 colspan=1>VR295</td><td rowspan=1 colspan=1>5.6 x 10^2 TCID50/0.2 ml</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A(H1NI) PR</td><td rowspan=1 colspan=1>VR95</td><td rowspan=1 colspan=1>1.8 x 104 TCID5o /0.2 ml</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Influenza A(H3N2) Aichci</td><td rowspan=1 colspan=1>VR547</td><td rowspan=1 colspan=1>1.8 x 106 TCID50 /0.2 ml</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Influenza A(H3N2) HongKong</td><td rowspan=1 colspan=1>VR544</td><td rowspan=1 colspan=1>5.6 x 104 TCID50/0.2 ml</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Influenza A FM</td><td rowspan=1 colspan=1>VR97</td><td rowspan=1 colspan=1>3.2 x 104 TCID50/0.2 ml</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Influenza A(H3N2) Victoria</td><td rowspan=1 colspan=1>VR822</td><td rowspan=1 colspan=1>1.8 x 106 TCID50 /0.2 ml</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Neg</td></tr></table>

One yeast and fourteen bacterial strains were obtained from ATCC or other commercial sources. Each cultured bacterial or yeast strain was diluted to a concentration of $1 \mathrm { ~ x ~ } 1 0 ^ { 8 }$ cfu/ml and tested on the SASTM FluAlert A&B Test. The results are summarized below.

<table><tr><td colspan="1" rowspan="1">Bacteria or Yeast</td><td colspan="1" rowspan="1">"A" portion of theSASTM FluAlertA&amp;B</td><td colspan="1" rowspan="1">"B" portion of theSASTM FluAlertA&amp;B</td></tr><tr><td colspan="1" rowspan="1">Candida albicans</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Chlamydia trachomatis</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium diphtheriae</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Haemophilus influenza</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Serratia marcescens</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus epidermidis</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus aureus</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Streptococcus sp gr A</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Streptococcus sp gr F</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Ncg</td></tr><tr><td colspan="1" rowspan="1">Streptococcus sp gr G</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Streptococcus pneumoniae</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Mycoplasma pneumoniae</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Neisseria meningitidis</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr></table>

Interference Study:

The analytical specificity of the A portion of the $\mathbf { S A S ^ { \mathbf { T M } } }$ FluAlert A&B was evaluated by testing a panel of 22 viruses, 14 bacteria, and one yeast species which may be found in the respiratory tract. For the A portion of the test, Influenza Whole Virus Strain A/FM/147 (ATCC VR97) at a titer of $7 . 9 \mathrm { ~ x ~ } 1 0 ^ { \hat { 3 } }$ $\mathrm { T C I D } _ { 5 0 } / 0 . 2$ ml. was added to viral cultures and viral antigens at the concentrations in the table below and bacterial and yeast cultures at concentrations of $1 \mathrm { ~ x ~ } 1 0 ^ { 8 } \mathrm { c f u / m l }$ For the B portion of the test, Influenza Whole Virus Strain $\mathrm { B } / \mathrm { M a s s } / 3 / 6 6$ (ATCC VR523) at a titer of $3 . 2 \mathrm { ~ x ~ } 1 \dot { 0 } ^ { 3 } \mathrm { T C I D } _ { 5 0 } / 0 . 2 \mathrm { ~ m l } .$ . was added to viral cultures in the concentrations in the table below and bacterial and yeast cultures at $1 \mathrm { { x } 1 0 ^ { 8 } \ c f u / m l }$ .

Results are summarized below:

<table><tr><td colspan="1" rowspan="1">Virus</td><td colspan="1" rowspan="1">ATTC/Lot#</td><td colspan="1" rowspan="1">Concentration</td><td colspan="1" rowspan="1">"A" Portion ofthe SASTMFluAlertA&amp;B</td><td colspan="1" rowspan="1">"B" Portion ofthe SASTMFluAlertA&amp;B</td></tr><tr><td colspan="1" rowspan="1">Adenovirus 5</td><td colspan="1" rowspan="1">10-198-000</td><td colspan="1" rowspan="1">1.2 x 10° TCIDso /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Adenovirus 7</td><td colspan="1" rowspan="1">VR7</td><td colspan="1" rowspan="1">3.2 x 10³ TCIDso /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Adenovirus 10</td><td colspan="1" rowspan="1">VR1087</td><td colspan="1" rowspan="1">3.2 x 10^³ TCID50/0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">CoxsackieA9</td><td colspan="1" rowspan="1">VR186</td><td colspan="1" rowspan="1">3.2 x 102 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">CoxsackieB5</td><td colspan="1" rowspan="1">VR185</td><td colspan="1" rowspan="1">3.2 x 106 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus</td><td colspan="1" rowspan="1">021301</td><td colspan="1" rowspan="1">20 μg/ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Echovirus1 1</td><td colspan="1" rowspan="1">VR1052</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Echovirus3</td><td colspan="1" rowspan="1">VR1040</td><td colspan="1" rowspan="1">1 x 104 TCID5o /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Echovirus6</td><td colspan="1" rowspan="1">VR1044</td><td colspan="1" rowspan="1">3.2 x 106 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">HSV-1</td><td colspan="1" rowspan="1">2J30000</td><td colspan="1" rowspan="1">15 μg/ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">HSV-2</td><td colspan="1" rowspan="1">8J29502</td><td colspan="1" rowspan="1">15 μg/ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Varicella zoster</td><td colspan="1" rowspan="1">1102097</td><td colspan="1" rowspan="1">12 μg/ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza 1</td><td colspan="1" rowspan="1">VR907</td><td colspan="1" rowspan="1">5.6 x 10° TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza 2</td><td colspan="1" rowspan="1">VR92</td><td colspan="1" rowspan="1">1.8 x 105 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Parainflucnza 3</td><td colspan="1" rowspan="1">VR93</td><td colspan="1" rowspan="1">3.2 x 106 TClD50 /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">RSV Long</td><td colspan="1" rowspan="1">VR26</td><td colspan="1" rowspan="1">0.1 x 1055 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">RSV B</td><td colspan="1" rowspan="1">VR1400</td><td colspan="1" rowspan="1">0.1 x 10525 TCID50/0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Influenza B Allen</td><td colspan="1" rowspan="1">VR102</td><td colspan="1" rowspan="1">3.2 x 10³ TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Influenza B Lee</td><td colspan="1" rowspan="1">VR101</td><td colspan="1" rowspan="1">3.2 x 10° TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Influenza B Mass</td><td colspan="1" rowspan="1">VR523</td><td colspan="1" rowspan="1">1.8 x 103 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Influenza B Maryland</td><td colspan="1" rowspan="1">VR296</td><td colspan="1" rowspan="1">1 x 104 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Influenza B Taiwan</td><td colspan="1" rowspan="1">VR295</td><td colspan="1" rowspan="1">5.6 x 102 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Pos</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Influenza A (HIN1) PR</td><td colspan="1" rowspan="1">VR95</td><td colspan="1" rowspan="1">1.8 x 104 TCID50 /0.2 ml</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Influenza A (H3N2) Aichci</td><td colspan="1" rowspan="1">VR547</td><td colspan="1" rowspan="1">1.8 x 10° TCIDso /0.2 ml</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Influenza A (H3N2) HongKong</td><td colspan="1" rowspan="1">VR544</td><td colspan="1" rowspan="1">5.6 x 104 TCID50 /0.2 ml</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Influenza A FM</td><td colspan="1" rowspan="1">VR97</td><td colspan="1" rowspan="1">3.2 x 104 TCID50 /0.2 ml</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Influenza A (H3N2)Victoria</td><td colspan="1" rowspan="1">VR822</td><td colspan="1" rowspan="1">1.8 x 10° TCID50 /0.2 ml</td><td colspan="1" rowspan="1">→</td><td colspan="1" rowspan="1">Pos</td></tr></table>

One yeast and fourteen bacterial strains were obtained from ATCC or other commercial sources. Each cultured bacterial or yeast strain was diluted to a concentration of $1 \mathrm { ~ x ~ } 1 0 ^ { 8 }$ cfu/ml and tested on the SASTM FluAlert A&B Test. The results are summarized below.

<table><tr><td rowspan=1 colspan=1>Bacteria or Yeast</td><td rowspan=1 colspan=1>&quot;A&quot; portion of theSASTM FluAlertA&amp;B</td><td rowspan=1 colspan=1>&quot;B&quot; portion of theSASTM FluAlertA&amp;B</td></tr><tr><td rowspan=1 colspan=1>Candida albicans</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Chlamydia trachomatis</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Corynebacterium diphtheriae</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Haemophilus influenza</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Klebsiella pneumoniae</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Serratia marcescens</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus epidermidis</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp gr A</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp gr F</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp gr G</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Streptococcus pneumoniae</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Mycoplasma pneumoniae</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Neisseria meningitidis</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr></table>

Expected Values:

Influenza prevalence varies year to year, with the highest number of cases in the fall and winter months in the US. During the period of September 30, 2007 to April 5, 2008, prevalence in the US for both influenza A and influenza B was $1 8 . 5 \% .$ with $74 \%$ of those cases attributed to influenza A and $2 6 \%$ attributed to influenza B. For studies conducted on the $\pmb { \mathrm { S A S } } ^ { \mathbf { T M } }$ FluAlert A&B Test, during the 2007-2008 and 2008-2009 seasons, prevalence for fresh, prospective nasal washes and nasal aspirates was $1 5 . 1 \%$ for influenza A and $1 6 . 5 \%$ for influenza B.

Conclusion of Performance Data:

The performance agreement of all clinical samples for the predicate devices and the proposed new device, FluAlert A&B, is $9 8 \%$ for the positive samples for influenza A, and $59 9 \%$ for negative samples, and is $> 9 7 \%$ for the positive samples for influenza B is and $5 9 9 \%$ for negative samples, indicating that the new device is substantially equivalent to the predicate devices

# JUL 28 2009

Robbi Perry Regulatory Affairs SA Scientific, Ltd. 4919 Golden Quail San Antonio, TX 78240

Re: K080380 Trade/Device Name: SASTM FluAlert A&B Regulation Number: 21 CFR 866.3330 Regulation Name: Influenza virus serological reagents Regulatory Class: Class II Product Code: GNX Dated: June 2, 2009 Received: June 4, 2009

Dear Ms. Perry:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device i classfied seeabove)into eitherclass Ⅱ Special Controls)or lass  (MA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/dsma/dsmamain.html. Sincerely yours,   
Hall attont   
Sally A. Hbjvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indication for Use

510(k) Number (if known): K080380

Device Name: SASTM FluAlert A & B Test

Indication For Use:

SAS™m FluAlert A & B Test is a visual and rapid assay for the presumptive in-vitro qualitative detection of Influenza A and Influenza B viral nucleoprotein antigens from nasal washes and nasal aspirates of symptomatic patients. The test is not intended for the dton  Inlueza Type iral ante.This tes or prossinal us

Negative results do not preclude infection with influenza A or influenza B and should not be used as the sole basis for treatment or other patient management decisions. It is recommended that negative results be confirmed by cell culture.

Division Sign-Off

# Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) 080180